Genetic Technologies Limited (GTG) is pleased to advise that it has executed an Exclusive Test Distribution and Services Agreement with Response Genetics, Inc., under which Genetic Technologies will become the exclusive distributor in Australia, Indonesia, Malaysia, the Philippines, Singapore and Thailand for Response Genetics’ ResponseDX: ColonTM, ResponseDX: LungTM and ResponseDX: GastricTM genetic test panels, proprietary PCR-based molecular diagnostic tests for cancer.
“ResponseDXTM tests offer physicians and their patients an objective way to chart a course of therapy during a very stressful time – the period between diagnosis and the start of treatment,” said Ms. Kathleen Danenberg, CEO and president of Response Genetics. “Based on encouraging sales and rapid adoption in the United States, we are pleased to partner with Genetic Technologies to make our ResponseDXTM tests available in Australia as well as in certain Asian countries.” Dr. Paul MacLeman, CEO of Genetic Technologies said “This is an important further step in Genetic Technologies’ move into advanced cancer management. As previously announced, we are seeking to leverage in-house developed tests through partnerships with third party developers of novel tests. This agreement, which follows similar distribution arrangements with Rosetta Genomics, Inc. and Trimgen, Inc., will assist us to expand our growing portfolio of genetic tools that will enable oncologists to more effectively manage patient diagnosis and therapy, improving treatment outcomes.
Response Genetics, Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999 and its principal headquarters are located in Los Angeles, California. Genetic Technologies was an early pioneer in recognising important new applications for “non- coding” DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
www.responsegenetics.com.
www.gtglabs.com.
